Switch theme
Sign up to access all valuation multiples
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.
2000
n/a
LTM Revenue $185M
LTM EBITDA $39.7M
$803M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medy-Tox has a last 12-month revenue (LTM) of $185M and a last 12-month EBITDA of $39.7M.
In the most recent fiscal year, Medy-Tox achieved revenue of $168M and an EBITDA of $28.7M.
Medy-Tox expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medy-Tox valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $185M | XXX | $168M | XXX | XXX | XXX |
| Gross Profit | $113M | XXX | $102M | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $39.7M | XXX | $28.7M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $25.6M | XXX | $14.9M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $20.5M | XXX | $12.4M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $24.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 14, 2025, Medy-Tox's stock price is KRW 163100 (or $120).
Medy-Tox has current market cap of KRW 1.07T (or $787M), and EV of KRW 1.10T (or $803M).
See Medy-Tox trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $803M | $787M | XXX | XXX | XXX | XXX | $2.95 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 14, 2025, Medy-Tox has market cap of $787M and EV of $803M.
Medy-Tox's trades at 4.8x EV/Revenue multiple, and 28.0x EV/EBITDA.
Equity research analysts estimate Medy-Tox's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medy-Tox has a P/E ratio of 38.4x.
See valuation multiples for Medy-Tox and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $787M | XXX | $787M | XXX | XXX | XXX |
| EV (current) | $803M | XXX | $803M | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | 20.2x | XXX | 28.0x | XXX | XXX | XXX |
| EV/EBIT | 31.4x | XXX | 53.8x | XXX | XXX | XXX |
| EV/Gross Profit | 7.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 38.4x | XXX | 63.3x | XXX | XXX | XXX |
| EV/FCF | 36.7x | XXX | 61.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedy-Tox's last 12 month revenue growth is 16%
Medy-Tox's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Medy-Tox's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medy-Tox's rule of X is 63% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medy-Tox and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 44% | XXX | 41% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medy-Tox acquired XXX companies to date.
Last acquisition by Medy-Tox was XXXXXXXX, XXXXX XXXXX XXXXXX . Medy-Tox acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medy-Tox founded? | Medy-Tox was founded in 2000. |
| Where is Medy-Tox headquartered? | Medy-Tox is headquartered in South Korea. |
| Who is the CEO of Medy-Tox? | Medy-Tox's CEO is Dr. Hyeon-Ho Jeong, PhD. |
| Is Medy-Tox publicy listed? | Yes, Medy-Tox is a public company listed on KRX. |
| What is the stock symbol of Medy-Tox? | Medy-Tox trades under 086900 ticker. |
| When did Medy-Tox go public? | Medy-Tox went public in 2009. |
| Who are competitors of Medy-Tox? | Similar companies to Medy-Tox include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Medy-Tox? | Medy-Tox's current market cap is $787M |
| What is the current revenue of Medy-Tox? | Medy-Tox's last 12 months revenue is $185M. |
| What is the current revenue growth of Medy-Tox? | Medy-Tox revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Medy-Tox? | Current revenue multiple of Medy-Tox is 4.3x. |
| Is Medy-Tox profitable? | Yes, Medy-Tox is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medy-Tox? | Medy-Tox's last 12 months EBITDA is $39.7M. |
| What is Medy-Tox's EBITDA margin? | Medy-Tox's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Medy-Tox? | Current EBITDA multiple of Medy-Tox is 20.2x. |
| What is the current FCF of Medy-Tox? | Medy-Tox's last 12 months FCF is $21.9M. |
| What is Medy-Tox's FCF margin? | Medy-Tox's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Medy-Tox? | Current FCF multiple of Medy-Tox is 36.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
